FDA APPROVES NEW INDICATION FOR ANTI-INFECTIVE AVELOX

The FDA has approved once-daily antibiotic Avelox (moxifloxacin HCl) for the treatment of complicated skin and skin structure infections (cSSSI) in adults caused by methicillin-susceptible staphylococcus aureus, escherichia coli, klebsiella pneumoniae or enterobacter cloacae. Avelox was developed by Bayer and is marketed in the U.S. by Schering-Plough, which acquired exclusive U.S. marketing rights to the drug in October 2004. The FDA approval to treat cSSSI is the fifth indication for Avelox, which is currently approved in the U.S. to treat acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community acquired pneumonia and uncomplicated skin and skin structure infections.